Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy

[1]  P. Ponikowski,et al.  Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. , 1997, Circulation.

[2]  P. Douglas,et al.  Growth hormone attenuates early left ventricular remodeling and improves cardiac function in rats with large myocardial infarction. , 1997, Journal of the American College of Cardiology.

[3]  M. Ranke,et al.  Diagnostics of endocrine function in children and adolescents , 2003 .

[4]  M. Thorén,et al.  The individual responsiveness to growth hormone (GH) treatment in GH-deficient adults is dependent on the level of GH-binding protein, body mass index, age, and gender. , 1996, The Journal of clinical endocrinology and metabolism.

[5]  B. Biondi,et al.  A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. , 1996, The New England journal of medicine.

[6]  R J Batista,et al.  Partial Left Ventriculectomy to Improve Left Ventricular Function in End‐Stage Heart Disease , 1996, Journal of cardiac surgery.

[7]  B Maisch,et al.  Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. , 1996, Circulation.

[8]  O. Alfieri,et al.  Impaired spontaneous growth hormone secretion in severe dialated cardiomyopathy. , 1996, American heart journal.

[9]  P. Douglas,et al.  Differential cardiac effects of growth hormone and insulin-like growth factor-1 in the rat. A combined in vivo and in vitro evaluation. , 1996, Circulation.

[10]  E. Sonnenblick,et al.  Stretch-induced programmed myocyte cell death. , 1995, The Journal of clinical investigation.

[11]  A. M. Lefer,et al.  Cardioprotective effect of insulin-like growth factor I in myocardial ischemia followed by reperfusion. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[12]  K. Michaelsen,et al.  Serum levels of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) in healthy infants, children, and adolescents: the relation to IGF-I, IGF-II, IGFBP-1, IGFBP-2, age, sex, body mass index, and pubertal maturation. , 1995, The Journal of clinical endocrinology and metabolism.

[13]  M C Oz,et al.  Reversal of chronic ventricular dilation in patients with end-stage cardiomyopathy by prolonged mechanical unloading. , 1995, Circulation.

[14]  R. Valcavi,et al.  Cardiac performance and mass in adults with hypopituitarism: effects of one year of growth hormone treatment. , 1995, The Journal of clinical endocrinology and metabolism.

[15]  J. Ross,et al.  Insulin-like growth factor-1 enhances ventricular hypertrophy and function during the onset of experimental cardiac failure. , 1995, The Journal of clinical investigation.

[16]  S. Coughlin,et al.  Idiopathic dilated cardiomyopathy. , 1994, The New England journal of medicine.

[17]  R. Kloner,et al.  Reperfusion injury induces apoptosis in rabbit cardiomyocytes. , 1994, The Journal of clinical investigation.

[18]  N. Skakkebaek,et al.  The ratio between serum levels of insulin‐like growth factor (IGF)‐I and the IGF binding proteins (IGFBP‐1, 2 and 3) decreases with age in healthy adults and is increased in acromegalic patients , 1994, Clinical endocrinology.

[19]  D. Johnston,et al.  Cardiovascular effects of growth hormone replacement therapy in hypopituitary adults. , 1994, European journal of endocrinology.

[20]  M. Konstam,et al.  Changes in ventricular volume, wall thickness and wall stress during progression of left ventricular dysfunction. The SOLVD Investigators. , 1993, Journal of the American College of Cardiology.

[21]  M. Ranke,et al.  Serum levels of insulin-like growth factor I (IGF-I) and IGF binding protein 3 reflect spontaneous growth hormone secretion. , 1993, The Journal of clinical endocrinology and metabolism.

[22]  B Kastler,et al.  Inter-study variability in left ventricular mass measurement. Comparison between M-mode echography and MRI. , 1992, European heart journal.

[23]  M. Russo,et al.  Reversible dilated cardiomyopathy due to growth hormone deficiency. , 1992, Chest.

[24]  C. Wiles,et al.  Growth hormone treatment in growth hormone-deficient adults. II. Effects on exercise performance. , 1991, Journal of applied physiology.

[25]  D. Donaldson,et al.  Growth hormone secretory profiles: variation on consecutive nights. , 1989, The Journal of pediatrics.

[26]  C. Higgins,et al.  Noninvasive evaluation of global left ventricular function with use of cine nuclear magnetic resonance. , 1989, Journal of the American College of Cardiology.

[27]  B. Sherman,et al.  Variability in the quantitation of circulating growth hormone using commercial immunoassays. , 1989, The Journal of clinical endocrinology and metabolism.

[28]  R W Parkey,et al.  Estimation of human myocardial mass with MR imaging. , 1988, Radiology.

[29]  H. Orskov,et al.  Increased myocardial contractility following growth hormone administration in normal man. An echocardiographic study. , 1988, Danish medical bulletin.

[30]  R S Reneman,et al.  Epicardial deformation and left ventricular wall mechanisms during ejection in the dog. , 1982, The American journal of physiology.